Lung Cancer Among People Who Never Smoked

American Lung Association Uncovers Stark Differences In Lung Cancer Survival, Screening And Treatment Across States

A new report from the American Lung Association reveals both progress and persistent challenges in the fight against lung cancer, which remains the leading cause of cancer deaths in the United States.

The "State of Lung Cancer" report, released Tuesday, shows a significant 26% improvement in survival rates over the past five years. However, the current five-year survival rate stands at just 28%, highlighting the continued severity of the disease.

Early detection remains crucial, with patients diagnosed in early stages seeing their survival chances soar to 64%. Unfortunately, more than 4 in 10 cases aren't caught until late stages, when survival rates drop to 9%. Despite this stark contrast, only 16% of eligible Americans underwent lung cancer screening in 2023, with rates varying dramatically by state — from a high of 28.6% in Rhode Island to just 9% in Wyoming.

The report identifies a critical gap in access to advanced diagnostic tools. Biomarker testing, which analyzes tumor DNA to guide treatment decisions, remains inconsistently covered by insurance across the country. Only 15 states currently mandate comprehensive coverage for this testing, while 30 states and Washington, DC, have no requirements in place.

Healthcare disparities continue to affect outcomes significantly. The report found that people of color consistently face worse outcomes across multiple metrics, including early diagnosis rates, survival rates and access to surgical treatment.

The American Lung Association is calling for nationwide policy changes, including universal insurance coverage for biomarker testing and passage of the Increasing Access to Lung Cancer Screening Act (HR 4286).

Lung Cancer: Raising The Alarm

Author: Dr Minish Jain, Senior Medical Oncologist, PuneNew Delhi: In the human chest, there are two remarkable sponge-like organs known as the lungs. When cancer begins its journey in these vital organs, it is referred to as lung cancer. This particular type of cancer stands out as the most prevalent globally and is the leading cause of cancer-related fatalities.

Recent global data reveals that in 2022, nearly 2.5 million individuals received a lung cancer diagnosis, while over 1.8 million tragically lost their lives to this disease. Such statistics remind us of the importance of awareness and proactive health measures in our communities.

Lung Cancer: Risk FactorsThe significant impact of lung cancer often masks a crucial truth: the majority of cases can be prevented. Tobacco smoking stands out as the leading risk factor, accounting for about 85% of cases, as reported by the World Health Organization (WHO). Additionally, various other contributors, such as second-hand smoke, outdoor and indoor air pollution, diesel exhaust, welding fumes, and asbestos, play their part in this serious health challenge.

Identifying the Signs of Lung Cancer: A crucial step for early awarenessHere are some of the key indicators that may suggest the presence of lung cancer:

A persistent cough that intensifies

Coughing up blood or rusty-colored mucus

Discomfort in the chest that worsens with deep breaths, coughing, or laughter

Changes in voice

Decreased appetite

Unexplained weight loss

Difficulty breathing

Persistent fatigue or weakness

Recurring respiratory infections, such as pneumonia

The sudden development of wheezing

These symptoms warrant careful consideration and timely consultation with a doctor.

Unraveling the complexities of Lung Cancer detectionThe doctor will take a moment to investigate an individual's medical background, seeking insights into the symptoms and potential risk factors. They will conduct a thorough examination to identify any indicators of lung cancer or other health issues. Should the medical history and physical assessment raise any concerns about lung cancer, further evaluations will be pursued. This may involve advanced imaging techniques such as chest X-rays, CT scans, MRI scans, or PET scans, as well as lung biopsies, to ensure a comprehensive understanding of the individual's health.

Biomarkers: Playing a pivotal role in treatment personalisationCurrently, just 16% of lung cancer patients survive five years post-diagnosis, largely due to late detection, which hinders our ability to enhance outcomes. To combat this challenge, there's a pressing need for innovative diagnostic tools that enable earlier identification of lung cancer, paving the way for timely interventions and ultimately reducing mortality rates.

Cancer biomarkers, distinct molecules that differentiate between healthy and cancerous states, have the potential to lead to the creation of a more effective diagnostic tool for lung cancer. These biomarkers can include proteins, genetic material like DNA, RNA, and lipids.

For patients already diagnosed with lung cancer, comprehensive biomarker testing is a critical step in precision medicine, ensuring that each patient receives a tailored treatment plan matched to their unique biomarker profile, maximizing the potential for effective outcomes at the optimal moment.

Tissue Biopsies: Tissue collection techniques include bronchoscopy, thoracoscopy, mediastinoscopy, etc. Once the tumor tissue is collected, it is forwarded to a laboratory for analysis, with the goal of conducting thorough biomarker testing.

Liquid Biopsies: A blood sample is analyzed in the laboratory for the presence of driver mutations.

Evolving landscape in Lung Cancer management Lung cancer treatment strategies are tailored to the specific cancer type, its extent of spread, and the patient's medical background. As many patients present with advanced stages of the disease, traditional approaches such as surgery, radiation, and chemotherapy often fall short of achieving complete cures, though they can enhance survival rates and alleviate symptoms.

In this evolving landscape, innovative therapies like targeted treatments and immunotherapies, particularly monoclonal antibodies, have shown remarkable potential. These groundbreaking options, whether used independently or in conjunction with existing therapies, have garnered FDA approval as first-line treatments for lung cancer, marking a significant shift from conventional methods.

The challenge is substantialOver the last ten years, significant advancements in research have improved survival rates for lung cancer, yet the challenge remains substantial. This disease impacts countless lives, extending its reach to everyone connected to those affected. It's time for us to reinvigorate our commitment to finding a cure and to motivate others to join us in this vital mission.

Source:

Disclaimer:

The information provided is for educational purpose only and does not substitute medical advice from your physician. Roche makes no representation with respect to any treatment action or application of medication through this educational endeavour and therefore will not be liable of any direct or indirect damage arising there from. Please consult your treating physician for any further advice and treatment.

Input Code: M-IN-00005356,

Validity: This input is not valid after 29th November 2025 or any update

Issued in Public Interest by:Roche Products (India) Pvt. Ltd. 146-B, 166 A, Unit No. 7, 8, 9, 8th Floor, R CityOffice, R City Mall, Lal Bahadur Shastri Marg, Ghatkopar, Mumbai - 400 086.Tel: +91(22)50457300, Fax: +91(22)50457301

Published On Dec 2, 2024 at 04:52 PM IST

Subscribe to our newsletter to get latest insights & analysis.

Can Lung Cancer Be Prevented? Identify The Risk Factors And Survival Rates

Access Denied

You don't have permission to access "http://www.Moneycontrol.Com/health-and-fitness/can-lung-cancer-be-prevented-identify-the-risk-factors-and-survival-rates-article-12878823.Html" on this server.

Reference #18.Cd24c317.1733185537.5710b59c

https://errors.Edgesuite.Net/18.Cd24c317.1733185537.5710b59c

---